CD36-Binding Amphiphilic Nanoparticles for Attenuation of α-Synuclein-Induced Microglial Activation

Neuroinflammation is one of the hallmarks contributing to Parkinson's disease (PD) pathology, where microglial activation occurs as one of the earliest events, triggered by extracellular alpha-synuclein (aSYN) binding to the cluster of differentation 36 (CD36) receptor. Herein, CD36-binding nanoparticles (NPs) containing tartaric acid-based amphiphilic macromolecules (AMs) are rationally designed to inhibit this aSYN-CD36 binding. In silico docking reveals that four AMs with varying alkyl side chain lengths present differential levels of CD36 binding affinity and that an optimal alkyl chain length promotes the strongest inhibitory activity toward aSYN-CD36 interactions. In vitro competitive binding assays indicate that the inhibitory activity of AM-based NPs plateaus at intermediate side chain lengths of 12 and 18 carbons, supporting the in silico docking predictions. These intermediate-length AM NPs also has significantly stronger effects on reducing aSYN internalization and inhibiting proinflammatory molecules tumor necrosis factor alpha (TNF-alpha) and nitric oxide from aSYN-challenged microglia. All four NPs modulate the gene expression of aSYN-challenged microglia, downregulating proinflammatory genes TNF, interleukin 6 (IL-6), and IL-1 beta, and upregulating anti-inflammatory genes transforming growth factor beta (TGF-beta) and Arg1 expression. Herein, overall, a novel polymeric nanotechnology platform is represented that can be used to modulate aSYN-induced microglial activation.

Automated summary

This study introduces a novel polymeric nanotechnology platform for modulating neuroinflammation by inhibiting aSYN-CD36 binding. Experimental results demonstrate that AM NPs with intermediate side chain lengths have the strongest inhibitory activity, reducing aSYN internalization and inhibiting the release of proinflammatory molecules.